Zhi-Ping Wu

Publications of Zhi-Ping Wu

• Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis.

  Authors: Shu Guang Zuo, Yan Chen, Zhi Ping Wu, Xin Liu, Chun Liu, Yong Chun Zhou, Cui Ling Wu, Cong Guo Jin, Yu Lan Gu, Jia Li, Xiao Qun Chen, Yong Li, Hui Ping Wei, Li Hua Li, Xi Cai Wang

  Biological & pharmaceutical bulletin. 02/2010; 33(2):174-82.

  The vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2), also called fetal liver kinase 1 (FLK1) in mice and kinase insert domain receptor (KDR) in humans, is an endothelial cell specificThe vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2), also called fetal liver kinase 1 (FLK1) in mice and kinase insert domain receptor (KDR) in humans, is an endothelial cell specific receptor tyrosine kinase that mediates lung cancer angiogenesis. We hypothesized that an active immunotherapy approach targeting FLK1 may inhibit lung cancer growth and metastasis. To test this hypothesis, we evaluated whether immune responses to FLK1 could be elicited in mice by immunization with an orally administered DNA vaccine encoding the extracellular domain (ECD) of FLK1 (pcDNA3.1-FLK1(ECD)) carried by attenuated Salmonella typhimurium. We found that the vaccine was effective at protective antitumor immunity in Lewis lung carcinoma models in mice by breaking immune tolerance to FLK1 self-antigen. Both FLK1-specific humoral and cellular immune responses against endothelial cells can be induced in mice by immunization with pcDNA3.1-FLK1(ECD). Immunization with pcDNA3.1-FLK1(ECD) resulted in tumor suppression and prolonged survival in mice challenged with Lewis lung carcinomas cells. Experimental pulmonary metastases were strongly inhibited in pcDNA3.1-FLK1(ECD) immunized mice challenged with Lewis lung carcinoma cells. Thus, we conclude that the plasmid DNA vaccine encoding the extracellular domain of FLK1 could be an important component of FLK1 DNA vaccine to prevent lung carcinoma recurrence and metastasis after surgery.

  Download

• [Detecting MUC-1 mRNA for Diagnosing Peripheral Blood Micro-metastasis in Non-small Cell Lung Cancer Patients.]

  Authors: Xiao-Qing Liu, Hong-Xuan Ren, Zhi-Ping Wu

  Ai zheng = Aizheng = Chinese journal of cancer. 12/2008; 27(12):1267-70.

  BACKGROUND & OBJECTIVE: Mucins, including MUC-1, are generally considered to be products of epithelial tissues and epithelial tumors. Theoretically, MUC-1 mRNA in peripheral blood with interstitialBACKGROUND & OBJECTIVE: Mucins, including MUC-1, are generally considered to be products of epithelial tissues and epithelial tumors. Theoretically, MUC-1 mRNA in peripheral blood with interstitial origin indicates metastasis. This study was to explore the feasibility of MUC-1 mRNA as a molecular marker in detecting peripheral blood micro-metastasis in patients with non-small cell lung cancer (NSCLC). METHODS: Nested reverse transcription-polymerase chain reaction (RT-PCR) was used to detect MUC-1 gene expression in peripheral blood samples from 60 patients with NSCLC, 15 patients with benign pulmonary disease, and 20 healthy subjects. MUC-1 gene expression in K562 and HL-60 cells with non-epithelial origin, and A549 and MCF-7 cells with epithelial origin was also detected by nested RT-PCR. RESULTS: The positive rates of MUC-1 mRNA were 80.0% in NSCLC group, 60.0% in benign pulmonary disease group, and 65.0% in healthy group. MUC-1 mRNA was also detected in K562, HL-60, A549 and MCF-7 cells. CONCLUSION: MUC-1 mRNA can not be a reliable detection marker for peripheral blood micro-metastasis in NSCLC patients.

• Two Novel Ceramides with a Phytosphingolipid and a Tertiary Amide Structure from Zephyranthes candida.

  Authors: Zhi-Ping Wu, Yu Chen, Bing Xia, Ming Wang, Yun-Fa Dong, Xu Feng

  Lipids. 11/2008;

  Two novel ceramides, Candidamide A (1) with a phytosphingolipid structure, and Candidamide B (2) with a tertiary amide structure, together with 12 known compounds (3-14) have been isolated from theTwo novel ceramides, Candidamide A (1) with a phytosphingolipid structure, and Candidamide B (2) with a tertiary amide structure, together with 12 known compounds (3-14) have been isolated from the bulbs of Zephyranthes candida, The structures of 1 and 2 have been elucidated to be 1,3,5,6-tetrahydroxy-2-(2'-hydroxytetracosanoyl amino)-8-(E)-octadecadiene (1) and (2S,3S,4R,8E,2'R)-2-[N-(2'-hydroxyoctadecanoyl)-N-(1'',2''-dihydroxyethyl)-amino]-8-hexacosene-1,3,4-triol (2) on the basis of spectroscopic evidence including IR, MS, NMR ((1)H-NMR, (13)C-NMR, DEPT, (1)H-(1)H COSY, HSQC, HMBC). The known compounds were identified as (2S)-3',7-dihydroxy-4'-methoxyflavan (3), (2S)-4'-hydroxy-7-methoxyflavan (4), (2S)-4',7-dihydroxyflavan (5), 7-hydroxy-3', 4'-methylenedioxyflavan (6), ambrettolide (7), beta-sitostero1 (8), beta-daucosterin (9), rutin (10), pancratistatin (11), lycorine (12), haemanthidine (13), and haemanthamine (14). In the antimicrobial assay, candidamide A (1) and candidamide B (2) displayed moderate activities against bacteria Staphylococcus aureus and Escherichia coli, and fungi Aspergillus niger, Candida albicans and Trichophyton rubrum.

• [Studies on chemical constituents from Zephyranthes candida]

  Authors: Zhi-Ping Wu, Yu Chen, Ming Wang, Yun-Fa Dong, Bing Xia, Xu Feng

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials. 11/2008; 31(10):1508-10.

  OBJECTIVE: To study on the chemical constituents of Zephyranthes candida. METHODS: Compounds were isolated and repeatedly purified by chromatographic techniques on silica gel column. Their structuresOBJECTIVE: To study on the chemical constituents of Zephyranthes candida. METHODS: Compounds were isolated and repeatedly purified by chromatographic techniques on silica gel column. Their structures were elucidated by chemical and spectral methods. RESULTS: Eight compounds were isolated from the whole plant of Zephyranthes candida, and identified as (2S)-3',7-dihydroxy-4'-methoxyflavan (I), beta-sitosterol (II), stigmasta-5,22-dien-3beta-ol (III), stigmasterol (IV), beta-daucosterin (V), Butylisobutyl phthalat (VI), Heptacosane (VII) and Ambrettolide (VIII). CONCLUSION: I-XIII are all isolated from this plant for the first time.

• A comparative study of gene vaccines encoding different extracellular domains of the vascular endothelial growth factor receptor 2 in the mouse model of colon adenocarcinoma CT-26.

  Authors: Jian Dong, Jun Yang, Ming-Qing Chen, Xi Cai Wang, Zhi Ping Wu, Yan Chen, Zhi Qiang Wang, Miao Li

  Cancer biology & therapy. 05/2008; 7(4):502-9.

  AIMS: To compare the immunogenicity and anti-tumor effects of gene vaccines encoding domains 1-4 with full length of extracellular region of VEGFR2. RESULTS: Both DNA vaccines decreased VEGF levelsAIMS: To compare the immunogenicity and anti-tumor effects of gene vaccines encoding domains 1-4 with full length of extracellular region of VEGFR2. RESULTS: Both DNA vaccines decreased VEGF levels and rose specific antibodies; the lymphocyte subsets of vaccinated mice maintained high; tumor latency period and survival time of immunized mice were prolonged; tumor size, weight, MVD and liver metastases were significantly less than the control groups. METHODS: Mouse model of CT-26 adenocarcinoma of colon were treated with orally immunized gene vaccine encoding extracellular 1-4 and full length of VEGFR2 respectively. The effect of anti-tumor was evaluated by detecting the tumor volume, mice survival time, intratumoral microvessel density (MVD) and liver metastases. To explore the reasonable mechanism of the oral gene vaccines, the levels of VEGF and anti-VEGFR2 antibody in serum were detected by ELISA, CD4+ and CD8+ T cells in peripheral blood and subcutaneous tumors were analyzed by flow cytometer and immunohischemistry respectively. CONCLUSION: Compared with full length of extracellular domain of VEGFR2, extracellular regions 1-4 of VEGFR2 has been sufficient to decrease the serum VEGF level and to inhibit tumor growth and metastasis specifically.

• [Determination of baicalin in Xiaoyanling Decoction by high-performance liquid chromatography]

  Authors: Jun-Yi Jian, Xiang Li, Rong-Li Qiu, Hai-Xia Zhang, Zhi-Ping Wu

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 01/2005; 3(1):54-6.

  OBJECTIVE: To establish a high-performance liquid chromatography (HPLC) method for the determination of baicalin in Xiaoyanling Decoction. METHODS: HPLC method was used for determination. A KromosilOBJECTIVE: To establish a high-performance liquid chromatography (HPLC) method for the determination of baicalin in Xiaoyanling Decoction. METHODS: HPLC method was used for determination. A Kromosil C18 column was used. The mobile phase consisted of MeOH-acid water (H(2)O:H(3)PO(4)=53:0.2) 40:60, and the detective wavelength was 277 nm. RESULTS: The content of baicalin in each Xiaoyanling Decoction sample was not less than 0.40 mg/ml (RSD<5%). CONCLUSION: The content of baicalin in Xiaoyanling Decoction is high and stable, and it can be used as the quality standard for Xiaoyanling Decoction.

• Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.

  Authors: Yan Chen, Tian Ning Zou, Zhi Ping Wu, Yong Chun Zhou, Yu Lan Gu, Xin Liu, Cong Guo Jin, Xi Cai Wang

  The International journal of biological markers. 25(2):59-68.

  To investigate the diagnostic, predictive, and prognostic value of the detection of circulating tumor cells (CTCs) using a three-marker (CK19, hMAM and CEA) RT-PCR assay in patients with early breastTo investigate the diagnostic, predictive, and prognostic value of the detection of circulating tumor cells (CTCs) using a three-marker (CK19, hMAM and CEA) RT-PCR assay in patients with early breast cancer. Peripheral blood was obtained from 50 patients with early-stage breast cancer before any systemic adjuvant therapy and analyzed for the presence of CK-19, hMAM and CEA mRNA-positive CTCs using an RT-PCR assay. The specificity of the primers used was evaluated in 20 healthy individuals, 24 patients with benign breast disease, and 30 patients with metastatic breast cancer. The detection of CTCs was correlated with clinical outcome. The detection rate of three-marker-positive CTCs in the blood of patients with early breast cancer was 54.0%, significantly higher than in patients with benign breast disease and healthy blood donors (p=0.002 and p=0.000, respectively). The three-marker RT-PCR assay had 58.8% sensitivity in the parallel test and 100% specificity for CTC detection in the serial test, which was higher than the sensitivity and specificity of single-marker assays. For early breast cancer, correlation analysis between detection of three-marker-positive CTCs and clinicopathological characteristics indicated that detection of threemarker-positive CTCs was significantly correlated with elevated serum CEA levels (p=0.001). After three years of follow-up, 13 of the 27 patients with three-marker-positive CTCs in their blood had relapsed and detection of three-marker-positive CTCs was significantly associated with locoregional recurrence and/or distant metastasis (p=0.002). Detection of three-marker-positive CTCs in peripheral blood was an independent risk factor for reduced median relapse-free interval (p=0.000). The three-marker RT-PCR assay can enhance the sensitivity and specificity of CTC detection compared to singlemarker assay. Detection of three-marker-positive CTCs was associated with relapse and might have important predictive and prognostic implications in early breast cancer.